FDA Hosts Virtual Meeting on Tracking Food by the Lot Number
Published Date: 5/28/2026
Notice
Summary
The FDA is hosting a virtual meeting on June 15, 2026, to talk about how to better track food by its lot number, making food safer and easier to trace. This affects food producers, sellers, and anyone involved in food safety, with a chance to suggest flexible ways to follow the rules. Comments on the ideas are open until July 15, 2026, so get involved and help shape the future of food tracking!
Analyzed Economic Effects
5 provisions identified: 4 benefits, 1 costs, 0 mixed.
Faster Recalls and Fewer Foodborne Illnesses
FDA states that lot-level tracking enables rapid tracing of contaminated foods during recalls, allowing the Agency to find sources faster, narrow recall scope, and remove affected products quickly, which results in fewer foodborne illnesses and deaths.
Enforcement Pause Through July 20, 2028
Congress directed FDA not to enforce the Food Traceability Rule prior to July 20, 2028 (Continuing Appropriations Act, Pub. L. 119-37). The original compliance date had been January 20, 2026 and FDA had proposed extending compliance to July 20, 2028.
Lot-Level Tracking Recordkeeping Requirement
The Food Traceability Rule requires businesses that manufacture, process, pack, or hold foods on FDA's Food Traceability List to assign unique Traceability Lot Codes that must be passed along unchanged (unless transformed) and to record Key Data Elements (KDEs) when performing Critical Tracking Events (CTEs) such as initial packing, transformation, and shipping.
FDA Stakeholder Meeting and Comment Opportunity
FDA will hold a virtual public meeting on June 15, 2026 (12:00-3:30 p.m. ET) to discuss lot-level traceability; registration is open until June 14, 2026 and speakers must register by June 5, 2026. Electronic or written comments on the meeting or the discussion paper are due by July 15, 2026 (comments accepted via https://www.regulations.gov until 11:59 p.m. ET on July 15, 2026).
Congressional Directive for Quarterly Engagement and 180‑Day Recommendations
Section 780 of the Continuing Appropriations Act directed FDA to engage quarterly with regulated entities to identify and implement, as appropriate, additional flexibilities for satisfying the Rule’s lot-level tracking requirement and said FDA should provide industry stakeholders with recommendations within 180 days of the Act's enactment.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14155 — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers design safe and smart clinical trials for psychedelic medicines, which could treat mental health and addiction issues. This update affects companies developing these drugs by giving clear rules to follow, speeding up research while keeping safety first. The guidance is effective now, and the FDA welcomes comments anytime, making it easier and clearer to bring these promising treatments to patients.
2026-14119 — Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
The FDA just released new rules for companies making generic skin creams with steroids. These rules explain how to prove their products work just as well as the original ones by testing on real people’s skin. This update affects drug makers and helps speed up safe, affordable medicine options starting now.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
Previous / Next Documents
Previous: 2026-10602 — AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program; Request for Information; Extension of Comment Period
The FDA is giving people more time to share their thoughts on a new pilot program that uses AI to make early clinical trials faster and smarter. This program could help researchers make better decisions and speed up how new medicines are tested. If you want to weigh in, you now have until June 29, 2026, to send your comments—no money changes yet, but this could shake up how trials run in the future!
Next: 2026-10605 — Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of a Previously Approved Collection; Title-Student Volunteer Service Agreement
The Drug Enforcement Administration wants to keep using a form that helps students, schools, and the agency agree on volunteer work rules. They’re asking for public feedback by July 27, 2026, to make sure the form is clear and easy to use without causing extra hassle. This keeps things smooth for student volunteers and the agency, with no new costs involved.